1	Al	al	SP+DA	-	-	0-2	344(3)_ANS_clinical_caseMIR	SENT1	-	-
2	haber	haber	VAN0000	-	-	3-8	344(3)_ANS_clinical_caseMIR	SENT1	-	-
3	tenido	tener	VMP00SM	-	-	9-15	344(3)_ANS_clinical_caseMIR	SENT1	-	-
4	un	un		C0205447_1	calificador_1	16-18	344(3)_ANS_clinical_caseMIR	SENT1	-	-
5	hijo	hijo	NCMS000	-	-	19-23	344(3)_ANS_clinical_caseMIR	SENT1	-	-
6	homocigoto	homocigoto	NCMS000	C0019904	hallazgo	24-34	344(3)_ANS_clinical_caseMIR	SENT1	-	-
7	F5O8del	F5O8del		-	-	35-42	344(3)_ANS_clinical_caseMIR	SENT1	-	-
8	,	,	Fc	-	-	42-43	344(3)_ANS_clinical_caseMIR	SENT1	-	-
9	el	el	DA0MS0	-	-	44-46	344(3)_ANS_clinical_caseMIR	SENT1	-	-
10	siguiente	siguiente	NC00SC0	C0332282	atributo	47-56	344(3)_ANS_clinical_caseMIR	SENT1	-	-
11	descendiente	descendiente	AQ0CS0	-	-	57-69	344(3)_ANS_clinical_caseMIR	SENT1	-	-
12	será	ser	VSIF3S0	-	-	70-74	344(3)_ANS_clinical_caseMIR	SENT1	-	-
13	portador	portador	AQ0MS0	C0560175	hallazgo	75-83	344(3)_ANS_clinical_caseMIR	SENT1	-	-
14	heterocigoto	heterocigoto	NCMS000	C0019425	calificador	84-96	344(3)_ANS_clinical_caseMIR	SENT1	-	-
15	(	(	Fpa	-	-	97-98	344(3)_ANS_clinical_caseMIR	SENT1	-	-
16	67	67	Z	-	-	98-100	344(3)_ANS_clinical_caseMIR	SENT1	-	-
17	%	%	Ft	-	-	100-101	344(3)_ANS_clinical_caseMIR	SENT1	-	-
18	)	)	Fpt	-	-	101-102	344(3)_ANS_clinical_caseMIR	SENT1	-	-
19	o	o	CC	-	-	103-104	344(3)_ANS_clinical_caseMIR	SENT1	-	-
20	de	de	SPS00	C0332285	atributo	105-107	344(3)_ANS_clinical_caseMIR	SENT1	-	-
21	genotipo	genotipo	NCMS000	C0017431	sustancia	108-116	344(3)_ANS_clinical_caseMIR	SENT1	-	-
22	homocigoto	homocigoto	NCMS000	C0019904	hallazgo	117-127	344(3)_ANS_clinical_caseMIR	SENT1	-	-
23	sin	sin	SPS00	C0332288	atributo	128-131	344(3)_ANS_clinical_caseMIR	SENT1	-	-
24	la	el	DA0FS0	-	-	132-134	344(3)_ANS_clinical_caseMIR	SENT1	-	-
25	mutación	mutación	NCFS000	-	-	135-143	344(3)_ANS_clinical_caseMIR	SENT1	-	-
26	(	(	Fpa	-	-	144-145	344(3)_ANS_clinical_caseMIR	SENT1	-	-
27	33	33	Z	-	-	145-147	344(3)_ANS_clinical_caseMIR	SENT1	-	-
28	%	%	Ft	-	-	147-148	344(3)_ANS_clinical_caseMIR	SENT1	-	-
29	)	)	Fpt	-	-	148-149	344(3)_ANS_clinical_caseMIR	SENT1	-	-
30	.	.	Fp	-	-	150-151	344(3)_ANS_clinical_caseMIR	SENT1	-	-

